主要目的：在健康受试者体内，分别在空腹和餐后条件下，以Pfizer Europe MA EEIG 持有的氯苯唑酸葡胺软胶囊（商品名： Vyndaqel®；规格：20 mg（按C14H7Cl2NO3.C7H17NO5 计））为参比制剂，石家庄科仁医药科技有限公司生产的氯苯唑酸葡胺软胶囊（规格：20 mg（按C14H7Cl2NO3.C7H17NO5 计））为受试制剂，研究两制剂的药代动力学，评价两制剂是否具有生物等效性。次要目的：观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Primary objective: To study the pharmacokinetics of clofazodone glucamine soft capsules (trade name: Vyndaqel®; specification: 20 mg (calculated as C14H7Cl2NO3.C7H17NO5)) held by Pfizer Europe MA EEIG as the reference preparation and clofazodone glucamine soft capsules (specification: 20 mg (calculated as C14H7Cl2NO3.C7H17NO5)) produced by Shijiazhuang Keren Pharmaceutical Technology Co., Ltd. as the test preparation in healthy subjects under fasting and postprandial conditions, and to evaluate whether the two preparations are bioequivalent. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date12 Jan 2024

Sponsor / Collaborator

Shijiazhuang Keren Medical Technology Co., Ltd.

NCT05489523 / RecruitingPhase 4IIT

An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation

Transthyretin cardiac amyloidosis (ATTR-CA) is a relentlessly progressive disease that can progress to end stage heart failure, at which point recently approved transthyretin production silencing or structure stabilizing therapies provide no clinical benefit. For well-selected individuals, heart transplantation is an excellent therapeutic option to improve survival. Historically, concomitant liver transplantation has been used to halt the progression of non-cardiac transthyretin amyloidosis (ATTR) manifestations, especially for individuals with TTR genotypes associated with significant neuropathy. However, despite this, patients continue to experience progressive non-cardiac manifestations, particularly gastrointestinal and neuropathic, which can have a substantial influence on post-heart transplantation morbidity. Concomitant liver transplantation is also associated with substantial morbidity and its future therapeutic role is questionable with recently established therapies for ATTR. Therefore, there is a clear unmet need to determine the utility and safety of ATTR targeted therapies for patients with recent heart transplantation for end-stage ATTR-CA. The central hypothesis of this proposal is that in patients who have received a heart transplantation for end-stage ATTR-CA, tafamidis therapy will be efficacious and well-tolerated. We aim to determine the safety and efficacy of tafamidis in stable patients who have undergone heart or combined heart/liver transplantation for ATTR (wild-type or variant) cardiac amyloidosis. The proposed study will be a single-arm intervention clinical trial with tafamidis. Because of the efficacy of tafamidis for both variant ATTR-CA and wild-type ATTR-CA, there is no clinical equipoise for an inactive-comparator placebo arm. The primary endpoint of this study will be serial change in plasma transthyretin (TTR) levels from baseline to 12 months at 3-month intervals. The secondary endpoints of this study will include serial changes in neuropathy assessments, modified body mass indices, incident transplant-specific adverse events, and pharmacokinetics of tafamidis. Observations from this study will establish the role of tafamidis use for the management of ATTR in patients after transplantation for end-stage ATTR-CA.

Start Date01 May 2023

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

CTR20222408 / CompletedNot Applicable

氯苯唑酸葡胺软胶囊人体生物等效性试验

[Translation] Bioequivalence study of clofazodone meglumine soft capsules in human body

以南京正大天晴制药有限公司研制的氯苯唑酸葡胺软胶囊（规格：20 mg）为受试制剂（T），Pfizer Europe MA EEIG持证、Catalent Pharma Solutions, LLC生产的氯苯唑酸葡胺软胶囊（商品名：维达全®，规格：20 mg）为参比制剂（R），研究受试制剂和参比制剂在空腹/餐后状态下单剂量给药时的药代动力学参数，进行人体生物等效性评价，并考察南京正大天晴制药有限公司研制的氯苯唑酸葡胺软胶囊的安全性。

[Translation]

The test preparation (T) was clofamid meglumine soft capsules (specification: 20 mg) developed by Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd., and the reference preparation (R) was clofamid meglumine soft capsules (trade name: Vidaquan®, specification: 20 mg) certified by Pfizer Europe MA EEIG and produced by Catalent Pharma Solutions, LLC. The pharmacokinetic parameters of the test preparation and the reference preparation when administered in a single dose under fasting/postprandial conditions were studied, the human bioequivalence was evaluated, and the safety of clofamid meglumine soft capsules developed by Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. was investigated.

Start Date13 Oct 2022

Sponsor / Collaborator

Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.

100 Clinical Results associated with Tafamidis Meglumine

100 Translational Medicine associated with Tafamidis Meglumine

100 Patents (Medical) associated with Tafamidis Meglumine

Literatures (Medical) associated with Tafamidis Meglumine

01 Jan 2024·Therapeutic advances in chronic disease

Tafamidis improves myocardial longitudinal strain in A97S transthyretin cardiac amyloidosis

Article

Author: Juang, Jimmy Jyh-Ming ; Lee, Ming-Jen ; Wu, Yuan-Kun Aden ; Tsai, Cheng-Hsuan ; Hsieh, Sung-Tsang ; Chou, Chia-Hung ; Lin, Yen-Hung ; Su, Mao-Yuan ; Cheng, Mei-Fang ; Lin, Siao-Ping ; Hsueh, Hsueh-Wen ; Chao, Chi-Chao ; Lin, Lung-Chun ; Shun, Chia-Tung ; Tseng, Ping-Huei ; Yu, An-Li

Background::

Transthyretin cardiomyopathy (ATTR-CM) is a debilitating disease that has received much attention since the emergence of novel treatments. The Transthyretin Cardiomyopathy Clinical Trial showed that tafamidis, a transthyretin tetramer stabilizer, effectively reduced the declines in functional capacity and quality of life. However, Ala97Ser (A97S) hereditary ATTR-CM is underrepresented in major ATTR-CM tafamidis trials.

Objectives::

We aim to investigate the change in global longitudinal strain (GLS) of A97S ATTR-CM patients after 12 months of tafamidis treatment.

Methods::

We retrospectively analysed a prospective cohort of patients with A97S ATTR-CM who received tafamidis meglumine (61 mg/day) at the National Taiwan University Hospital. Echocardiography with speckle tracking strain analysis was performed at baseline and 12 months after treatment.

Results::

In all, 20 patients were included in the cohort. The baseline left ventricular ejection fraction (LVEF) and interventricular septum (IVS) thickness were 59.20 ± 13.23% and 15.10 ± 3.43 mm, respectively. After 12 months of tafamidis treatment, the LVEF and IVS were 61.83 ± 15.60% ( p = 0.244) and 14.59 ± 3.03 mm ( p = 0.623), respectively. GLS significantly improved from −12.70 ± 3.31% to −13.72 ± 3.17% ( p = 0.048), and longitudinal strain (LS) in apical and middle segments significantly improved from −16.05 ± 4.82% to −17.95 ± 3.48% ( p = 0.039) and −11.89 ± 4.38% to −13.58 ± 3.12% ( p = 0.039), respectively. Subgroup analysis showed that patients with LVEF < 50% had a better treatment response and improvement in GLS. The patients with an IVS ⩾ 13 mm had an improvement in two-chamber LS from −10.92 ± 4.25% to −13.15 ± 3.87% ( p = 0.042) and an improvement in apical left ventricular LS from −15.30 ± 5.35% to −17.82 ± 3.99% ( p = 0.031).

Conclusion::

Tafamidis significantly improved GLS, and particularly apical and middle LS in A97S ATTR-CM patients.

01 Jan 2024·JAMA cardiology

Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy

Article

Author: Fine, Nowell ; Weissman, Neil J ; Maurer, Mathew S ; Boman, Kurt ; Elliott, Perry ; Shah, Sanjiv J ; Gundapaneni, Balarama ; Fernandes, Fabio ; Klein, Allan L ; Garcia-Pavia, Pablo ; Sultan, Marla B

Importance:

Tafamidis has been shown to improve survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo. However, its effect on cardiac function has not been fully characterized.

Objective:

To examine the effect of tafamidis on cardiac function in patients with ATTR-CM.

Design, Setting, and Participants:

This was an exploratory, post hoc analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), a multicenter, international, double-blind, placebo-controlled phase 3 randomized clinical trial conducted from December 2013 to February 2018. The ATTR-ACT included 48 sites in 13 counties and enrolled patients aged 18 to 90 years with ATTR-CM. Data were analyzed from July 2018 to September 2023.

Intervention:

Patients were randomized to tafamidis meglumine, 80 mg or 20 mg, or placebo for 30 months.

Main Outcomes and Measures:

Patients were categorized based on left ventricular (LV) ejection fraction at enrollment as having heart failure with preserved ejection fraction (≥50%), mildly reduced ejection fraction (41% to 49%), or reduced ejection fraction (≤40%). Changes from baseline to month 30 in LV ejection fraction, LV stroke volume, LV global longitudinal strain, and the ratio of early mitral inflow velocity to septal and lateral early diastolic mitral annular velocity (E/e′) were compared in patients receiving tafamidis, 80 mg, vs placebo.

Results:

A total of 441 patients were randomized in ATTR-ACT, and 436 patients had available echocardiographic data. Of 436 included patients, 393 (90.1%) were male, and the mean (SD) age was 74 (7) years. A total of 220 (50.5%), 119 (27.3%), and 97 (22.2%) had heart failure with preserved, mildly reduced, and reduced LV ejection fraction, respectively. Over 30 months, there was less pronounced worsening in 4 of the echocardiographic measures in patients receiving tafamidis, 80 mg (n = 176), vs placebo (n = 177) (least squares mean difference: LV stroke volume, 7.02 mL; 95% CI, 2.55-11.49; P = .002; LV global longitudinal strain, −1.02%; 95% CI, −1.73 to −0.31; P = .005; septal E/e′, −3.11; 95% CI, −5.50 to −0.72; P = .01; lateral E/e′, −2.35; 95% CI, −4.01 to −0.69; P = .006).

Conclusions and Relevance:

Compared with placebo, tafamidis, 80 mg, attenuated the decline of LV systolic and diastolic function over 30 months in patients with ATTR-CM. Approximately half of patients had mildly reduced or reduced LV ejection fraction at enrollment, suggesting that ATTR-CM should be considered as a possible diagnosis in patients with heart failure regardless of underlying LV ejection fraction.

Trial Registration:

ClinicalTrials.gov Identifier: NCT01994889

03 Jul 2023·Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Tafamidis concentration required for transthyretin stabilisation in cerebrospinal fluid

Article

Author: Powers, Evan T. ; Jaeger, Marcus ; Tsai, Felix J. ; Coelho, Teresa ; Kelly, Jeffery W.

BACKGROUND:

Hereditary transthyretin (TTR) amyloidosis (ATTRv) initially presents as a polyneuropathy and/or a cardiomyopathy. Central nervous system (CNS) pathology in ATTRv amyloidosis, including focal neurological episodes, dementia, cerebrovascular bleeding, and seizures, appears around a decade later. Wild-type (WT) TTR amyloidosis (ATTRwt) causes a cardiomyopathy. CNS pathology risk likely also increases in these patients as cardiomyopathy progresses. Herein, we study tafamidis-mediated TTR kinetic stabilisation in cerebrospinal fluid (CSF).

METHODS:

Varying tafamidis concentrations (50-1000 nM) were added to CSF from healthy donors or ATTRv patients, and TTR stabilisation was measured via the decrease in dissociation rate.

RESULTS:

Tafamidis meglumine (Vyndaqel) can be dosed at 20 or 80 mg QD. The latter dose is bioequivalent to a 61 mg QD dose of tafamidis free acid (Vyndamax). The tafamidis CSF concentration in ATTRv patients on 20 mg Vyndaqel is ∼125 nM. By linear extrapolation, we expect a CSF concentration of ∼500 nM at the higher dose. When tafamidis is added to healthy donor CSF at 125 or 500 nM, the WT TTR dissociation rate decreases by 42% or 87%, respectively.

CONCLUSIONS:

Tafamidis stabilises TTR in CSF to what is likely a clinically meaningful extent at CSF concentrations achieved by the normal tafamidis dosing regimen.

News (Medical) associated with Tafamidis Meglumine

01 May 2024

·firstwordpharma.com

Pfizer ups profit view on smaller drop in Paxlovid demand, leaner operations

Pfizer reported better-than-expected first-quarter revenue and raised its full-year profit outlook on Wednesday, benefiting from its broad cost-cutting programme, a smaller-than-feared drop in sales of its oral COVID-19 antiviral Paxlovid, and strong performance from some of its other products.The pharma now expects to book adjusted earnings of $2.15 to $2.35 per share for the year, up from its prior guidance of $2.05 to $2.25 per share. Pfizer also reiterated its previous revenue forecast of $58.5 billion to $61.5 billion.Paxlovid softens post-pandemic blowIts COVID-19 products, the vaccine Comirnaty it shares with BioNTech and oral antiviral Paxlovid, saw significant sales decreases as demand has sunk to new lows. However, the declines were less severe than anticipated.Paxlovid booked $2 billion in sales for the quarter, down 50% from the same period a year ago, yet coming in well above the $762.5 million analysts were expecting. The company recorded a $771-million favourable adjustment due to the return of unused Paxlovid treatment courses by the US government. Meanwhile, Comirnaty generated $354 million, down 88% from the year-earlier period and falling short of projections of $496.5 million.Oncology boost from SeagenExcluding COVID-19 products, Pfizer said revenue for the first quarter rose 11%. Growth was partly fueled by the company's $43-billion acquisition of Seagen, whose legacy products including the targeted cancer therapies Padcev and Adcetris contributed a combined $742 million in quarterly revenue. However, Adcetris sales still fell short of analyst expectations.Other non-COVID-19 products that helped spur sales growth included the blood thinner Eliquis (+9% to $2 billion), the Vyndaqel family of cardiomyopathy drugs (+66% to $1.1 billion), and the Prevnar pneumococcal vaccine franchise (+6 to $1.7 billion).However, Pfizer's new RSV vaccine Abrysvo saw just $145 million in sales, far short of analysts' estimate of $360 million, while the breast cancer drug Ibrance posted an 8% decline in revenue to $1.1 billion.Cost cuts fuel outlook raise"We believe stronger new launch performance and further progress on the pipeline will be necessary to change the current narrative on the stock," commented JP Morgan analyst Chris Schott.Pfizer said its updated profit guidance "takes into consideration our confidence in delivering on our cost realignment programme target," adding it is on track to deliver at least $4 billion in savings by the end of the year.First-quarter sales totaled $14.9 billion overall, which was 20% lower than the same period a year ago, while net income was down 44% at $3.1 billion.Pipeline cutsMeanwhile, the drugmaker also culled some programmes from its pipeline, including discontinuing development of VTX-801, a gene therapy candidate partnered with Vivet Therapeutics that was in Phase I for Wilson's disease. In addition, it scrapped potential new indications for its S1P inhibitor Velsipity (etrasimod) in atopic dermatitis and alopecia areata, as well as a migraine prevention programme for its oral CGRP receptor antagonist Zavzpret (zavegepant), all of which had reached Phase II testing.

VaccineAcquisitionPhase 2Phase 1Gene Therapy

01 May 2024

·www.biospace.com

Pfizer Beats Q1 Forecast Despite 20% Revenue Drop, Cuts Four Pipeline Programs

Pictured: Pfizer's sign at its head office in Quebec, Canada/iStock, JHVEPhoto Pfizer announced its first-quarter 2024 earnings on Wednesday, reporting a 20% year-over-year decline in revenue attributable to the steep drop in demand for its COVID-19 products. Nevertheless, the company’s first-quarter revenue of $14.88 billion beat analysts’ consensus estimates, which were at around $14 billion. Pfizer’s net income in the quarter was nearly $3.12 billion or $0.55 per share, a 44% plunge from its net income of a little more than $5.54 billion or $0.97 per share during the same time period in 2023. The strong performance of Pfizer’s product portfolio—excluding its COVID-19 franchise—helped the pharma exceed analyst expectations. If not for its coronavirus business, Pfizer’s revenues would have jumped 11%, according to the company. Looking ahead to the rest of 2024, Pfizer raised its profit guidance and now expects adjusted earnings per share of $2.15 to $2.35, up from a previous estimate of $2.05 to $2.25. The pharma now also forecasts a full-year revenue range of between $58.5 billion to $61.5 billion. Pfizer’s BMS-partnered anticoagulant Eliquis (apixaban) was its top-performing asset, generating $2.04 billion in Q1 2024, up 10% year-over-year. The company’s $43 billion Seagen acquisition, which closed in December 2023, also contributed heavily to the pharma’s financial performance in the quarter, bringing in $742 million in global legacy revenue. The Vyndaqel (tafamidis meglumine) family of products—which includes Vyndamax (tafamidis) and Vynmac (tafamidis) and which is indicated for cardiomyopathy—also performed well in Q1, with revenues growing 66% globally to nearly $1.14 billion. Meanwhile, its oncology franchise was led by the breast cancer treatment Ibrance (palbociclib), which was hit with a 7% sales decline but still brought in more than $1.05 billion in the quarter. Despite recording a 50% year-over-year drop in sales, Pfizer’s COVID-19 pill Paxlovid (nirmatrelvir/ritonavir) nevertheless earned almost $2.04 billion in Q1, suggesting a successful commercial transition in the U.S. The company’s coronavirus mRNA vaccine Comirnaty brought in $354 million in the quarter, down 88%. CEO Albert Bourla said in a statement that he is “encouraged” by these overall results in Q1 which point to a “well-executed quarter,” allowing the company to soften the blow of the COVID-19 earnings cliff. “We intend to build on this positive momentum in the quarters ahead.” To set the company up for sustainable growth this year, Pfizer on Wednesday also cleaned up its pipeline, announcing that four programs have been discontinued. The pharma terminated the development of VTX-801, a recombinant gene therapy being developed for Wilson disease, as well as Zavzpret (zavegepant) which it was trialing as an oral preventative treatment for migraine. Pfizer also axed two Phase II studies for the S1P blocker Velsipity (etrasimod)—one in atopic dermatitis and the other in alopecia areata. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

VaccineAcquisitionmRNAPhase 2IPO

01 May 2024

·www.biopharmadive.com

Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life

Pfizers rare disease drug Vyndaqel may be its least well known blockbuster medicine. The pharmaceutical companys COVID-19 vaccine became a household name during the pandemic, while its other top-sellers for blood clots, breast cancer and pneumococcal infections are routinely and widely advertised on TV.Yet during the first quarter, it was Vyndaqel that outperformed expectations, delivering sales that substantially exceeded Wall Street forecasts. The drug, which treats the cardiac form of a rare disease called transthyretin amyloidosis, brought in $1.1 billion between January and March, 25% higher than the consensus estimate of just over $900 million.Worldwide sales were $686 million during the same period last year. In a Wednesday earnings statement, Pfizer said Vyndaqels growth was due to continued strong uptake, primarily in certain European countries and in the U.S., where it is sold as Vyndamax.Salim Syed, an analyst at Mizuho Securities, wrote in a client note that uptake may have been boosted by the Inflation Reduction Act, which capped out-of-pocket costs for people covered by Medicare Part D. Syed estimated the cap taking effect in 2024 should reduce out-of-pocket spending by about $10,000.The strong sales prompted several analysts, speaking on a conference call, to press Pfizer executives on the drugs remaining patent life. The basic product patent is set to expire at the end of this year in the U.S., and in 2026 in Europe.Several generic drugmakers filed last year for U.S. approval of copycat versions, and Pfizer has sued them for patent infringement.The company also hopes to extend the drugs market exclusivity through 2028, and has filed requests for patent term extensions that are currently pending. If granted, the extension could help protect billions of dollars in annual sales for Pfizer as the company resets following sales declines for its COVID vaccine and antiviral drug.Those COVID sales declines continue to weigh on Pfizer, which reported total revenue in the first quarter of $14.9 billion, down about 20% from the same period a year ago. Excluding COVID products, revenue was up 11% operationally.Vyndaqels sales growth, and its looming patent questions, are also important to would-be competitors BridgeBio Pharma and Alnylam Pharmaceuticals. BridgeBio is currently awaiting a Food and Drug Administration approval decision for its drug acoramidis in the same condition Vyndaqel treats. A verdict is due from the agency by late November.Meanwhile, Alnylam is anticipating results by June or July from an important study of its drug vutrisiran, the success or failure of which will determine whether it could compete with Vyndaqel.Shares in BridgeBio were up nearly 5% in Wednesday morning trading, while Alnylams rose by about 2%. '

VaccinePatent InfringementDrug ApprovalmRNAAcquisition

100 Deals associated with Tafamidis Meglumine

External Link

KEGG	Wiki	ATC	Drug Bank
D09674	Tafamidis Meglumine	N07XX08	DB11644

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Transthyretin Amyloid Cardiomyopathy	AU	Pfizer Inc.	16 Mar 2020
Amyloid Neuropathies	CN	Pfizer Europe MA EEIG	05 Feb 2020
Cardiomyopathies	US	FoldRx Pharmaceuticals LLC	03 May 2019
Amyloid Neuropathies, Familial	JP	Pfizer Japan, Inc.	20 Sep 2013
Amyloidosis, Hereditary, Transthyretin-Related	EU	Pfizer Europe MA EEIG	16 Nov 2011
Amyloidosis, Hereditary, Transthyretin-Related	IS	Pfizer Europe MA EEIG	16 Nov 2011
Amyloidosis, Hereditary, Transthyretin-Related	LI	Pfizer Europe MA EEIG	16 Nov 2011
Amyloidosis, Hereditary, Transthyretin-Related	NO	Pfizer Europe MA EEIG	16 Nov 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Poikiloderma With Neutropenia	Phase 3	AR	Pfizer Inc.	01 Jul 2008
Poikiloderma With Neutropenia	Phase 3	BR	Pfizer Inc.	01 Jul 2008
Poikiloderma With Neutropenia	Phase 3	FR	Pfizer Inc.	01 Jul 2008
Poikiloderma With Neutropenia	Phase 3	DE	Pfizer Inc.	01 Jul 2008
Poikiloderma With Neutropenia	Phase 3	PT	Pfizer Inc.	01 Jul 2008
Poikiloderma With Neutropenia	Phase 3	SE	Pfizer Inc.	01 Jul 2008
Senile cardiac amyloidosis	Phase 2	US	Pfizer Inc.	01 Aug 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05498701 (CTgov)	Phase 1	-	22	Tafamidis Free Acid (Tafamidis Free Acid 12.2 mg Oral Tablet (Fasted))	hxvimevrwv(vhdcmrsoyv) = nzqqnfvyyx gpjimcdkpm (myzyhtmcxk, cdzlshuouq - cccdnjquii) View more	-	03 Jun 2024
				Tafamidis Meglumine (Tafamidis Meglumine 20 mg Oral Capsule (Fasted))	hxvimevrwv(vhdcmrsoyv) = ejgkznuoqp gpjimcdkpm (myzyhtmcxk, hykmpiactj - bktlwztpav) View more
NCT05482308 (CTgov)	Phase 1	-	12	Tafamidis Free Acid (Variant 12.2 mg Tafamidis Free Acid Tablet (Test))	kjenpuztkw(bythxdexiv) = mhahutyjfn nhvlhxpmgf (ltinhnzcbo, tnzzgezziq - oxzqheizyk)	-	23 May 2024
				Tafamidis Free Acid (Proposed Commercial 12.2 mg Tafamidis Free Acid Tablet (Reference))	kjenpuztkw(bythxdexiv) = zrnerdhkts nhvlhxpmgf (ltinhnzcbo, ehexwjhlum - tbtdvefoqh) View more
NCT04828993 (CTgov)	Phase 4	Amyloid Neuropathies, Familial	15	Tafamidis Meglumine	rbrlqxezcv(wfobwoxvhl) = mmijpcevxy ckwmvrdmga (scnepwygtu, nngbqnjqcm - ktmakizlvm) View more	-	12 Mar 2024
NCT02146378 (Pubmed \| Med Lett Drugs Ther)	Not Applicable	Amyloidosis, Hereditary, Transthyretin-Related	219	Tafamidis Meglumine 20 mg/d	odzqctrdfd(svcpcoeumi) = ppizncbbio unlcgfvgbz (fuoqbxtexc ) View more	-	01 Sep 2020
ATTR-ACT (ESC2019)	Not Applicable	Transthyretin Amyloid Cardiomyopathy variant (ATTRm) \| wild-type (ATTRwt) TTR	-	Tafamidis meglumine	oprqdfshec(kkjbjxxtjc): hazard ratio = 0.64 (95% CI, 0.47 - 0.85), P-Value = 0.001	Positive	01 Sep 2019
				Placebo
NCT00694161 (Pubmed \| Circ Heart Fail) Manual	Phase 2	Transthyretin Amyloid Cardiomyopathy	31	tafamidis	czpheinuqy(gtsjouelhp) = borzenusds szehwwrpps (iwpwvgzxje ) View more	Positive	01 May 2015
NCT00694161 (CTgov)	Phase 2	Senile cardiac amyloidosis \| Cardiomyopathies	35	tafamidis (Fx-1006A)	wsxcgnsaib(xtxtewyzsz) = tvluecqcrx qvonfjoklw (dambnkeqxy, cxyaqzcrgy - wniiwtwurw) View more	-	18 Dec 2012
NCT00791492 (CTgov)	Phase 2/3	Poikiloderma With Neutropenia \| Amyloid Neuropathies, Familial	86	Tafamidis (Tafamidis-Tafamidis)	qtayfpuhvz(ofcjeioxox) = llwgeugfbt clirffyaiz (wsrqjqdyzk, mfgpzkenmu - ejaiapvygg) View more	-	17 Dec 2012
				Tafamidis+Placebo (Placebo-Tafamidis)	qtayfpuhvz(ofcjeioxox) = setcngdgjx clirffyaiz (wsrqjqdyzk, qccqafjqhn - ywweefmqjy) View more
NCT00409175 (CTgov)	Phase 2/3	Amyloid Neuropathies, Familial	128	Tafamidis (Fx-1006A) (Tafamidis)	ymxnvznugo(nriiwylaio) = aezjnzqnqi bktikdurnl (zoknoakljv, iigywlqplv - hyfqmsouvd) View more	-	17 Dec 2012
				tafamidis (Fx-1006A) (Placebo)	ymxnvznugo(nriiwylaio) = zbhzpemggh bktikdurnl (zoknoakljv, eprlezsaot - mendufuxff) View more
NCT00630864 (CTgov)	Phase 2	Amyloidosis, Hereditary, Transthyretin-Related	21	tafamidis (Fx-1006A)	omhtutomhm(jsekmfkqyd) = bbixkqbofk vpoytincyp (lnoacowzol, pmfzywahxd - cguuirydjb) View more	-	17 Dec 2012

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis